Horizon Therapeutics To Buyback Up To $500 Mln Of Ordinary Shares
(RTTNews) - Biotechnology company Horizon Therapeutics plc (HZNP) today announced that its Board of Directors authorized the repurchase of up to $500 million of the Company's ordinary shares.
Under the program, the Company may repurchase ordinary shares from time to time on the open market or through privately negotiated transactions or structured repurchase transactions.
As of June 30, 2022, the Company had cash and cash equivalents of $1.89 billion. The Company expects to fund the repurchase of its ordinary shares under the program with existing cash and cash equivalents.
read more
Amgen, Horizon Therapeutics Reach Settlement On FTC Lawsuit; Seeks To Close Acquisition In Q4
Amgen (AMGN) and Horizon Therapeutics plc (HZNP) announced Friday the entry into a consent order agreement with the Federal Trade Commission (FTC) that resolves the pending FTC administrative lawsuit. This clears the path to take the final steps to close Amgen's $27.8 billion acquisition of Horizon.
RTTNews
|
517 days ago
Horizon Says UPLIZNA Approved By Brazilian Health Regulatory Agency As Monotherapy For NMOSD
Biotechnology company Horizon Therapeutics plc (HZNP) announced Tuesday that the Brazilian Health Regulatory Agency (ANVISA) has approved UPLIZNA as a monotherapy for the treatment of adult patients with NMOSD who are AQP4-IgG+.
RTTNews
|
772 days ago
Xeris Biopharma Inks Research Collaboration With Horizon Therapeutics To Develop Teprotumumab
Biopharmaceutical company Xeris Biopharma Holdings, Inc. (XERS) announced Wednesday that it has entered into a research collaboration and option agreement with Horizon Therapeutics plc (HZNP).
RTTNews
|
799 days ago
Horizon Says Phase 2 Trial Of Dazodalibep To Treat Sjögren's Syndrome Met Primary Endpoint
Horizon Therapeutics plc (HZNP) announced Monday that its Phase 2 trial evaluating dazodalibep for the treatment of Sjögren's syndrome met the primary endpoint in patients with moderate-to-high systemic disease activity. Sjögren's syndrome is a disease with no FDA-approved treatments available.
RTTNews
|
871 days ago
Australian Market Halves Gains In Mid-market
The Australian stock market has halved its early gains in mid-market trading on Friday, but extending the gains in the previous two sessions, following the broadly positive cues from Wall Street overnight. The benchmark S&P/ASX 200 is moving well above the 8,500 level after hitting all-time highs, with gains is mining and technology stocks partially offset by weakness in financial stocks.
RTTNews
|
5h 24min ago
Sensex, Nifty Seen Higher At Open
Indian shares are seen opening on a positive note Friday as investors await the release of the Economic Survey 2025 in Parliament.
RTTNews
|
5h 45min ago
Thai Stock Market Poised To Open In The Green
The Thai stock market has finished lower in back-to-back sessions, sinking more than 10 points or 0.7 percent along the way. The Stock Exchange of Thailand now sits just above the 1,335-point plateau and it's likely to find support on Friday.
RTTNews
|
6h 46min ago
Japanese Market Slightly Higher
Adding to the gains in the previous two sessions, the Japanese market is slightly higher on Friday, following the broadly positive cues from Wall Street overnight. The Nikkei 225 is staying well above the 39,500 level, as traders react positively to some upbeat domestic economic data, with retail sales exceeded expectations and unemployment rate dropping.
RTTNews
|
6h 47min ago
